SANUWAVE Health, Inc. Revises Revenue Guidance for the Fourth Quarter Ending of December 31, 2016
January 26, 2017 at 09:00 am EST
Share
SANUWAVE Health, Inc. revised revenue guidance for the fourth quarter ending of December 31, 2016. For the quarter, the company achieved revenue in a range of $640,000 to $650,000 for its fourth quarter ending December 31, 2016 compared to previously announced expectations of $450,000 to $650,000 of revenue for the fourth quarter.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
